ATTY. DOCKET NO. U. S DEPARTMENT OF COMMERCE SERIAL NO. ·FÒRM PTO-1449 PATENT AND TRADEMARK OFFICE U 014840-0 10/679,961 APPLICANT INFORMATION DISCLOSURE STATEMENT BY APPLICANT Robert SEEMAYER, et al. (Use several sheets if necessary) FILING DATE **GROUP** October 6, 2003 1625 U.S. PATENT DOCUMENTS DOCUMENT FILING DATE IF **EXAMINER** REFERENCE INITIALS APPROPRIATE DESIGNATION NUMBER DATE NAME 10/1992 LOWE, III 5,162,339 AAAB OFFICE OF PETITIONS AC ADAE ΑF AGΑH ΑI ΑJ AK. FOREIGN PATENT DOCUMENTS **DOCUMENT** TRANSLATION NUMBER DATE COUNTRY YES NO AL AMAN AO ΑP OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.) Seward, E. M., "Quinuclidine-Based NK-1 Antagonists 1: 3-Benzyloxy-1-Azabicyclo[2.2.2]Octanes", Bioorganic & Medical Chemistry Letters, Vol. 3, No. 6, pp. 1361-AR 1366, 1993

OTHER ART (Including Author, Title, Date, Pertinent Dates, Btc.)

Seward, E. M., "Quinuclidine-Based NK-1 Antagonists 1: 3-Benzyloxy-1-Azabicyclo[2.2.2]Octanes", Bioorganic & Medical Chemistry Letters, Vol. 3, No. 6, pp. 1361-1366, 1993

AS

DATE CONSIDERED 12/15/44

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.